Navigation Links
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Date:11/7/2008

income 236,308 207,474 781,435 955,149

Research and

development income - - - 621,222

Total revenues 236,308 207,474 781,435 1,749,448

Operating expenses

Marketing and selling 116,840 198,520 545,579 673,776

Research and

development 2,307,103 2,236,852 4,387,636 5,410,226

General and

administrative 947,684 1,017,177 3,242,614 3,305,918

3,371,627 3,452,549 8,175,829 9,389,920

Facility lease

termination

Gain from lease

buyout (4,100,000) - (4,100,000) -

Expenses related

to relocation

and lease Buyout 116,867 - 116,867 -

Total facility

lease buyout (3,983,133) - (3,983,133) -

Total operating

expenses (611,506) 3,452,549 4,192,696 9,389,920

Income or (loss)

from operations 847,814 (3,245,075) (3,411,261) (7,640,472)

Other income (expense)

Interest income 45,858 160,080 205,530 550,402

Interest expense (3,393) (5,191) (11,565) (10,967)

Other 91 - 1,329 2,941

Total other

income (expense) 42,556 154,889 195,294 542,376

Net income or (loss) $890,370 $(3,090,186) $(3,215,967) $(7,098,096)

Net income (loss)

per share, basic

and diluted $ .02 $(0.08) $(0.08) $(0.19)

Shares used in

computing basic

net income (loss)

per share 41,043,770 38,153,316 41,037,128 38,123,071

Shares used in

computing diluted

net income
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
3. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
4. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Calif., Dec. 14 The Roberts ... today released the analysis of social responsibility ... world-wide. The report contains a compilation of ... environmental and social reporting of the companies. ... and performance for both environmental and social ...
(Date:12/14/2009)... According to Millennium Research Group ... market intelligence, Japan,s complex regulatory environment and ... significant lag in peripheral vascular stenting device ... developed nations. MRG,s new Japanese ... report finds, however, that recent indication-specific device ...
(Date:12/14/2009)... The U.S. Food and Drug Administration (FDA) ... Suspension for the treatment of schizophrenia in adults, ... ) announced today. ZYPREXA RELPREVV, a long-acting intramuscular ... to four weeks. ,, Different from both oral ... allow for stable concentrations of the active drug ...
Breaking Medicine Technology:New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 2New Report Grades Sustainability Reporting of Top Pharmaceutical Companies 3Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014 2Japanese Peripheral Vascular Stent Procedures to Experience 11% Growth Through 2014 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8FamilyLife Supports Military Marriages in Atlanta 62459 1FamilyLife Supports Military Marriages in Atlanta 62459 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 1Ministerial Roundtable Discusses Future of Medical Tourism 62455 2Ministerial Roundtable Discusses Future of Medical Tourism 62455 3Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 1Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 2Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 3Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 4Peregrine Completes Patient Enrollment in Cotara 28R 29 Dose Confirmation and Dosimetry Brain Cancer Trial 15048 5
... England, December 8 , ... Completed Price and,Reimbursement Approval for Tetrabenazine in H1 2009 ... Distribution Rights Granted in Finland (MediFront) and Taiwan,(Giddi Pharma); ... Cambridge Laboratories Limited ...
... 7 Millennium: The Takeda Oncology,Company today ... randomized, multi-center,Company-sponsored Phase I/II study of VELCADE, ... previously untreated multiple,myeloma (MM). The preliminary analysis ... of four drugs was generally well tolerated ...
Other Medicine Technology:Cambridge Laboratories Announces Approval of Tetrabenazine in Spain 2Cambridge Laboratories Announces Approval of Tetrabenazine in Spain 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 2Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 3Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 4Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 5Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients 6
(Date:12/15/2009)... Veinwave Eliminates Spider Veins and Telangiectasia , ... (PRWEB) December 10, 2009 ... and telangiectasia – those unsightly clusters of red, blue or ... In fact, for Western populations like the US, it’s been estimated that ... , , , , ,Although the Veinwave has been ...
(Date:12/15/2009)... Ill. A study in the Dec. 15 ... Medicine indicates that significant associations exist between ... regurgitation and headaches in young school-aged children. ... parent-reported insomnia was 3.3 times more likely in ... likely in children with headaches. Nineteen percent ...
(Date:12/14/2009)... particles carry oxygen, drugs, and more… , ... ... Santa Barbara, in collaboration with scientists at University of Michigan, ... key functions of natural red blood cells, including softness, flexibility, ... , ,The primary function of natural red blood cells is ...
(Date:12/14/2009)... 14 Americold Realty Trust ("Americold") announced today ... S-11 with the U.S. Securities and Exchange Commission (the ... its common shares. The number of shares to be ... not yet been determined. The common shares to be ... by Americold. ,, The joint book-running managers of ...
(Date:12/14/2009)... WASHINGTON, Dec. 14 The National Organization for ... an immediate end to lifetime and annual health insurance ... Politico, a newspaper distributed widely on Capitol Hill, ... loopholes that would allow caps to continue for most ... "NORD supports health care reform and welcomes the promises ...
Breaking Medicine News(10 mins):Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3Health News:Synthetic Red Blood Cells Developed 2Health News:Synthetic Red Blood Cells Developed 3Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2
... prisoners has failed to solve the crisis that is ... the BMA today. ,The 19th July marks ... introduction of emergency measures designed to alleviate the overcrowding ... of the Government strategy was an early release programme ...
... a long-standing belief that male circumcision can reduce HIV ... AIDS conference will be told next week . ... Society (IAS) conference to be held in Sydney from ... major development in HIV prevention. ,"We always ...
... a product recall in US without a Chinese link. Following ... a Georgia facility are being withdrawn in USA. ... canned foods in nearly four decades. ,Health officials ... leading brands like Castleberry's, Kroger and Austex . ...
... rise in the number of Australian HIV cases in the ... risky sexual behaviour in men having sex with men, and ... emerge, according to research published online for the Medical Journal ... Professor of Epidemiology at the National Centre in HIV Epidemiology ...
... Some chain-smokers are reluctant or incapable of quitting smoking, but ... they smoke each day . ,However, after studying ... very little attention has been given to this alternative of ... effort in therapies aimed at smokers has been at helping ...
... non-pyrethroid insecticide, propoxur, and a repellent, N,N-diethyl toluamide ... synergy against mosquitoes responsible for malaria transmission to ... had proved to be much more effective than ... nets soaked with this mixture had a lethal ...
Other Medicine News:Health News:Prison Healthcare Continues to Fail Despite Emergency Measures, Warns BMA 2Health News:Male Circumcision can Cut HIV Infection, Studies Show 2Health News:Chilly Sauce Linked to Botulism, Forcing Recall in US 2Health News:Chilly Sauce Linked to Botulism, Forcing Recall in US 3Health News:HIV Cases Increasing In Australia 2Health News:Chain Smokers Prepared to Lessen Their Daily Cigs Rather Than Quitting 2Health News:Insecticide and Repellent Combo Effective in Eliminating Malarial Mosquitoes 2
... monoclonal antibody based colorimetric test intended ... gonorrhoeae. The test requires less than ... heating or pretreatment. The test does ... cultures. GonoGen&trade II eliminates agglutination, guesswork, ...
... a monoclonal antibody based coagglutination ... identification of Neisseria gonorrhoeae. The ... viable or fresh cultures. After ... minute rotation, a positive reaction ...
Rapid Test Kit...
... a novel device for the growth ... and Neisseria meningitidis. This product ... is easily transportable as a self-contained ... and examine the growth of organisms ...
Medicine Products: